Compare DTCX & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DTCX | ECOR |
|---|---|---|
| Founded | N/A | 2005 |
| Country | United States | United States |
| Employees | 2 | N/A |
| Industry | EDP Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.3M | 81.0M |
| IPO Year | N/A | 2018 |
| Metric | DTCX | ECOR |
|---|---|---|
| Price | $1.81 | $6.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | ★ 127.3K | 70.3K |
| Earning Date | 04-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $32,032,000.00 |
| Revenue This Year | N/A | $33.60 |
| Revenue Next Year | N/A | $30.40 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 27.20 |
| 52 Week Low | $1.51 | $4.16 |
| 52 Week High | $3.80 | $10.50 |
| Indicator | DTCX | ECOR |
|---|---|---|
| Relative Strength Index (RSI) | 37.76 | 38.51 |
| Support Level | $1.68 | $5.69 |
| Resistance Level | $2.27 | $7.35 |
| Average True Range (ATR) | 0.13 | 0.55 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 10.42 | 30.99 |
Datacentrex Inc is a digital infrastructure and capital deployment company that owns and operates Scrypt compute assets and evaluates strategic transactions across asset-backed operating businesses. Its current operating platform is centered on owned and operated Scrypt-based proof-of-work compute deployed through third-party colocation facilities. Datacentrex monetizes this compute through hashrate marketplace mechanisms and manages a treasury of digital assets and cash in a manner intended to preserve capital and support opportunistic, accretive deployment. The company's operations are principally operated remotely at various data centers throughout the United States.
electroCore Inc is a bioelectronic technology company whose mission is to improve health and quality of life through non-invasive bioelectronic technologies. Its two commercial products are gammaCore non-invasive vagus nerve stimulation, or nVNS, and Quell Fibromyalgia, or Quell. It also sells Truvaga and TAC-STIM products, which are handheld, personal-use consumer products developed to promote general wellness and human performance. It operates in one segment: Bioelectronic Innovations. Geographically, it operates in the United States, the United Kingdom, Japan, and Other.